Reata Pharmaceuticals Inc
NASDAQ:RETA
Reata Pharmaceuticals Inc
Revenue
Reata Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Reata Pharmaceuticals Inc
NASDAQ:RETA
|
Revenue
$23.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45B
|
CAGR 3-Years
2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$60.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
Reata Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Reata Pharmaceuticals Inc
Breakdown by Segments
Reata Pharmaceuticals Inc
Total Revenue:
2.2m
USD
|
License And Milestone:
1.6m
USD
|
Other Revenue:
568k
USD
|
See Also
What is Reata Pharmaceuticals Inc's Revenue?
Revenue
23.5m
USD
Based on the financial report for Jun 30, 2023, Reata Pharmaceuticals Inc's Revenue amounts to 23.5m USD.
What is Reata Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 5Y
-18%
Over the last year, the Revenue growth was 135%. The average annual Revenue growth rates for Reata Pharmaceuticals Inc have been 15% over the past three years , -18% over the past five years .